Literature DB >> 2492333

Hemorrhage produces abnormalities in lymphocyte function and lymphokine generation.

E Abraham1, A A Freitas.   

Abstract

Hemorrhage has been shown to produce abnormalities in lymphocyte function, particularly in the proliferative response to mitogens such as PHA and Con A. In order to better examine the hemorrhage-induced alterations in immune function, we determined the effects of blood loss in mice without any surgical manipulation on lymphocyte populations and subpopulations, cellular activation, and lymphokine production. Hemorrhage induced no changes in cell numbers in the spleen, thymus, lymph nodes, and bone marrow. No alterations in the relative percentages of B (B220+, mu+) and T (Lyt-1+, Lyt-2+, T3+, L3T4+) cell subpopulations were found in any organ after blood loss. Significant decreases in splenocyte proliferation in response to Con A, IL-2R expression and blast formation occurred after hemorrhage. IFN-gamma production increased 24 and 48 h post hemorrhage. Decreases in IL-2, IL-3, and IL-5 generation were present 2 h after blood loss. IL-2 production remained significantly decreased for 48 h posthemorrhage, then increased to more than twice normal levels 72 h posthemorrhage, and subsequently returned to prehemorrhage values. These results demonstrate that hemorrhage produces widespread alterations in immune function without affecting lymphocyte population and subpopulation numbers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2492333

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  The influence of laparoscopy on lymphocyte subpopulations in the surgical patient.

Authors:  V L Vallina; J M Velasco
Journal:  Surg Endosc       Date:  1996-05       Impact factor: 4.584

Review 2.  Transfusion-associated microchimerism: the hybrid within.

Authors:  Evan M Bloch; Rachael P Jackman; Tzong-Hae Lee; Michael P Busch
Journal:  Transfus Med Rev       Date:  2012-10-24

3.  The 5-lipoxygenase pathway is required for acute lung injury following hemorrhagic shock.

Authors:  John C Eun; Ernest E Moore; David C Mauchley; Chris A Johnson; Xianzhong Meng; Anirban Banerjee; Max V Wohlauer; Simona Zarini; Miguel A Gijón; Robert C Murphy
Journal:  Shock       Date:  2012-06       Impact factor: 3.454

4.  Early IL-2/sIL-2R surge following surgery leads to temporary immune refractoriness.

Authors:  N Lahat; R Shtiller; A Y Zlotnick; G Merin
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

5.  Distinct roles of trauma and transfusion in induction of immune modulation after injury.

Authors:  Rachael P Jackman; Garth H Utter; Marcus O Muench; John W Heitman; Matthew M Munz; Robert W Jackman; Hope H Biswas; Ryan M Rivers; Leslie H Tobler; Michael P Busch; Philip J Norris
Journal:  Transfusion       Date:  2012-03-27       Impact factor: 3.157

6.  Effects of haemorrhage on bacterial antigen specific pulmonary plasma cell function.

Authors:  A Robinson; E Abraham
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

7.  Defective macrophage antigen presentation following haemorrhage is associated with the loss of MHC class II (Ia) antigens.

Authors:  A Ayala; M M Perrin; I H Chaudry
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

8.  Engagement of CD44 by hyaluronan suppresses TLR4 signaling and the septic response to LPS.

Authors:  Jun Muto; Kenshi Yamasaki; Kristen R Taylor; Richard L Gallo
Journal:  Mol Immunol       Date:  2009-09-24       Impact factor: 4.407

9.  The release of transforming growth factor-beta following haemorrhage: its role as a mediator of host immunosuppression.

Authors:  A Ayala; D R Meldrum; M M Perrin; I H Chaudry
Journal:  Immunology       Date:  1993-07       Impact factor: 7.397

10.  Effects of therapy with soluble tumour necrosis factor receptor fusion protein on pulmonary cytokine expression and lung injury following haemorrhage and resuscitation.

Authors:  E Abraham; W F Coulson; M D Schwartz; J Allbee
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.